Search

Your search keyword '"Claire Corrigan"' showing total 3 results
Start Over Author "Claire Corrigan"
3 results on '"Claire Corrigan"'

1. Diagnostic uncertainty presented barriers to the timely management of acute thrombotic thrombocytopenic purpura in the United Kingdom between 2014 and 2019

Author

Tom P. Bull, Rory McCulloch, Phillip L.R. Nicolson, Andrew J. Doyle, Rebecca J. Shaw, Alexander Langridge, Zara Sayar, David L. Tucker, Michala Pettit, Rita Perry, William Thomas, Catherine Page, Ioana Whalley, Tina Dutt, Louise Garth, Will Lester, Richard J. Buka, Mary Subhan, Victoria Ware, Rachel Rayment, Daniel Castle, Astrid Etherington, Luke Carter‐Brzezinski, Jayne Peters, Claire Corrigan, Narind Sharma, Gary Benson, Sarah Challenor, Thomas S. Skinner, Rui Zhao, Lyndsay A.G. McLeod‐Kennedy, Kenneth Douglas, Amy Knott, Sophie Smith, Julia Wolf, Sophie A. Todd, Vickie McDonald, Alexandros Rampotas, Christopher Dean, Gavinda Sangha, Sue Pavord, Nicholas Denny, Sarah Jaafar, David P.T. McLaughlin, Jennifer E. Ross, Mamatha Karanth, Sarah L. Beverstock, Lynn Mansonso, Samuel H. Burrows, Sudhir Tauro, Amir Shenouda, Benjamin M. Bailiff, Daniel Kajita, Joannes Hermans, Harshita Goradia, Emily M. Finan, Sarah Alford, Keir Pickard, Brigit Greystoke, Thomas Fail, Asmaa Abdussalam, Lara N Roberts, James B. Clark, Natalie Heeney, Jennifer Young, Jamie Maddox, Swathy Srinath, Jahanzeb Khawaja, Jayne Parkes, Samah Babiker, Beverley J. Hunt, Sarah L. Wheeldon, Paul Kerr, Molham Tahhan, Mark Vickers, Alexandra C. Pike, Quentin Hill, Nadreen Mustafa, Azza Almaremi, Emily Hughes, Sean J.F. McGoldrick, Eleana Loizou, Izabela James, Sara R. Boyce, Isabel Farmer, Murugaiyan Thanigaikumar, Katherine Wickenden, Richard Gooding, Kathryn Thornton, Clare Kane, Adam Cole, JessicaC Griffin, Suzanne Docherty, Kiri I. Dixon, Josephine Crowe, Mathew Sheridan, Corinne De Lord, Amit Sud, Anna Austin, Nichola Coooper, Chris Bailey, Luke Attwell, Rachel Hall, Benjamin Gray, Salena R. Chauhan, Anand Lokare, Amy Gudger, Claire Horgan, Indrani Venkatadasari, Israa Kaddam, Claire L. Mapplebeck, Joost Van Veen, Maya Raj, Kanchana De Abrew, Edward Belsham, Cecilia Gyansah, Shalal Sadullah, Beena Salhan, Richard Murrin, Rhys L. Williams, Andrew Stewart, Naomi Cornish, Sophie Otton, Zeeshan Khan, Sam Ackroyd, Lucia Y. Chen, Nicholas P. Lafferty, Francesca Leonforte, Nicholas Pemberton, Emanal Rawi, Diana Triantafyllopoulou, Jagdish Adiyodi, Jun Yong, Elizabeth Jones, David Davies, Rachel C. Peck, Robson Philip, Thomas Seddon, Paul Cahalin, Catherine Prodger, David A. Dutton, Alexander J. Sternberg, Rajani Chengal, Paolo Polzella, and Marie Scully

Subjects
Adult, Treatment Outcome, Plasma Exchange, Purpura, Thrombotic Thrombocytopenic, Uncertainty, Humans, Hematology, Retrospective Studies
Abstract

Acute thrombotic thrombocytopenic purpura (TTP) is a life-threatening emergency and plasma exchange (PEX) is the initial treatment shown to reduce acute mortality.To compare current practice in the United Kingdom (UK) against the standards set out in the 2012 British Society of Haematology guideline, and to better understand the issues affecting prompt initiation of PEX.The trainee research network HaemSTAR conducted a retrospective nationwide review of adults presenting to UK hospitals with a first episode of acute TTP.Data on 148 patients treated at 80 UK hospitals between 2014 and 2019 demonstrated that 64.8% of patients received PEX within 24 h. Diagnostic uncertainty was the most commonly cited reason for delayed treatment. Conversely, a shorter time to PEX occurred in patients who had red cell fragments or severe thrombocytopenia identified on their first complete blood count. Availability of on-site PEX was associated with a greater proportion of patients receiving PEX within 8 h compared to patients transferred, but by 24 h there was no difference between the two groups and two-thirds of all patients had received their first PEX. The mortality rate for patients that received PEX was 9.2%, with 27.8% of deaths linked to delayed treatment initiation.This is the first multi-center evaluation of treatment delays in acute TTP and it will inform targeted pathways to improve prompt access to life-saving intervention.

Published
2022
Full Text
View/download PDF

2. Admissions of Children and Adolescents With Deliberate Self-harm to Intensive Care During the SARS-CoV-2 Outbreak in Australia

Author

Claire, Corrigan, Graeme, Duke, Johnny, Millar, Eldho, Paul, Warwick, Butt, Michael, Gordon, Jacinta, Coleman, David, Pilcher, Felix, Oberender, and Breanna, Pellegrini

Subjects
Adult, Male, Adolescent, Critical Care, SARS-CoV-2, Australia, Infant, Newborn, COVID-19, General Medicine, Intensive Care Units, Pediatric, Cohort Studies, Humans, Female, Child, Pandemics, Self-Injurious Behavior, Retrospective Studies
Abstract

Identification of potential indirect outcomes associated with the COVID-19 pandemic in the pediatric population may be essential for understanding the challenges of the current global public health crisis for children and adolescents.To investigate whether the SARS-CoV-2 outbreak and subsequent effective public health measures in Australia were associated with an increase in admissions to intensive care units (ICUs) of children and adolescents with deliberate self-harm (DSH).This national, multicenter cohort study was conducted using the Australian data subset of the binational Australian and New Zealand Paediatric Intensive Care registry, a collaborative containing more than 200 000 medical records with continuous contributions from all 8 Australian specialist, university-affiliated pediatric ICUs, along with 1 combined neonatal-pediatric ICU and 14 general (adult) ICUs in Australia. The study period encompassed 6.5 years from January 1, 2015, to June 30, 2021. Patients aged 12 to 17 years were included. Data were analyzed from December 2021 through February 2022.Any of the following admission diagnoses: ingestion of a drug, ingestion of a nondrug, hanging or strangulation, or self-injury.The primary outcome measure was the temporal trend for national incidence of DSH ICU admissions per 1 million children and adolescents aged 12 to 17 years in Australia.A total of 813 children and adolescents aged 12 to 17 years admitted to ICUs with DSH were identified among 64 145 patients aged 0 to 17 years in the Australian subset of the registry during the study period. Median (IQR) age was 15.1 (14.3-15.8) years; there were 550 (67.7%) female patients, 261 (32.2%) male patients, and 2 (0.2%) patients with indeterminate sex. At the onset of the pandemic, monthly incidence of DSH ICU admissions per million children and adolescents increased from 7.2 admissions in March 2020 to a peak of 11.4 admissions by August 2020, constituting a significant break in the temporal trend (odds ratio of DSH ICU admissions on or after vs before March 2020, 4.84; 95% CI, 1.09 to 21.53; P = .04). This occurred while the rate of all-cause admissions to pediatric ICUs of children and adolescents of all ages (ie, ages 0-17 years) per 1 million children and adolescents decreased from a long-term monthly median (IQR) of 150.9 (138.1-159.8) admissions to 91.7 admissions in April 2020.This cohort study found that the coronavirus pandemic in Australia was associated with a significant increase in admissions of children and adolescents to intensive care with DSH.

Published
2022

3. Rapid Translation of COVID-19 Preprint Data into Critical Care Practice

Author

Aidan J. C. Burrell, Ary Serpa Neto, Tony Trapani, Tessa Broadley, Craig French, Andrew A. Udy, Adam Visser, Adrian Mattke, Adrian Regli, Alan Rashid, Alexis Tabah, Alison Walker, Allen Cheng, Amanda Corley, Andrew Udy, Anil Ramnani, (Isabel) Anne Leditschke, Anthony Eidan, Bart DeKeulenaer, Baumik Mevavala, Ben Mulholland, Benjamin Reddi, Brent Richards, Cameron Knott, Cara Moore, Carmel Delzoppo, Catherine Boschert, Catherine Tacon, Claire Corrigan, Danielle Austin, David Brewster, David Cooper, David Crosbie, David Hawkins, Edda Jessen, Eduardo Martinez, Edward Fysh, Edward Litton, Felix Oberender, Forbes McGain, Gavin Salt, Glenn Eastwood, Gopal Taori, Hannah Thompson, Hayden White, Hergen Buscher, Ian Seppelt, Ifrah Khan, Janelle Young, Jayshree Lavana, Jeremy Cohen, Jessica Lugsdin, Jill Garlick, Jim Buttery, John Botha, John Santamaria, Jonathan Barrett, Kasha Singh, Kevin Laupland, Khaled El-Khawas, Kristine Estensen, Kush Deshpande, Kyle White, Leigh Fitzpatrick, Lewis Campbell, Mahesh Ramanan, Manoj Saxena, Marie Draper, Marion Kainer, Mark Kol, Mark Page, Mark Plummer, Martin Sterba, Matthew Anstey, Matthew Brain, Matthew Maiden, Myrene Kilminster, Naomi Hammond, Neeraj Bhadange, Nicole Humphreys, Paras Jain, Paul Azzi, Paul Secombe, Paula Lister, Peter Chan, Peter McCanny, Phillip Britton, Pierre Janin, Rashmi Runiyar, Ravi Krishnamurthy, Ravikiran Sonawane, Ravindranath Tiruvoipati, Rebecca Jessup, Richard Totaro, Rinaldo Bellomo, Ritesh Sanghavi, Samantha Bates, Sandra Peake, Shailesh Bihari, Shane George, Sharon Waterson, Simon Erickson, Steve Webb, Subhash Arora, Subodh Ganu, Thomas Rozen, Toni McKenna, Umesh Kadam, Vineet Nayyar, Wei Han Choy, Wisam Albassam, and Intensive Care Medicine

Subjects
Pulmonary and Respiratory Medicine, Male, medicine.medical_specialty, Critical Care, medicine.medical_treatment, MEDLINE, Disease, Critical Care and Intensive Care Medicine, medicine.disease_cause, Dexamethasone, 03 medical and health sciences, 0302 clinical medicine, Adrenal Cortex Hormones, Intensive care, Pandemic, Correspondence, medicine, Humans, 030212 general & internal medicine, Practice Patterns, Physicians', Intensive care medicine, Survival rate, Coronavirus, Aged, Mechanical ventilation, Aged, 80 and over, Clinical Trials as Topic, business.industry, Australia, COVID-19, Middle Aged, COVID-19 Drug Treatment, Survival Rate, Treatment Outcome, 030228 respiratory system, Female, Guideline Adherence, business, medicine.drug
Abstract

To the Editor: The global coronavirus disease (COVID-19) pandemic has seen a significant increase in the use of preprint services to enable the widespread dissemination of research findings (1). However, whether such facilities influence practice change is currently unknown. Here, we describe the impact of the preprint release and eventual publication of the RECOVERY (Randomised Evaluation of COVID-19 Therapy) trial (2) on corticosteroid use in clinical practice in Australian ICUs. The RECOVERY trial tested the efficacy of dexamethasone (6 mg by mouth or intravenously for up to 10 d) in hospitalized patients with clinically suspected or confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and demonstrated a reduction in 28-day mortality, particularly in those receiving either mechanical ventilation or oxygen. Before these results, the Australian and New Zealand Intensive Care Society COVID-19 guidelines recommended against the routine use of corticosteroids (3).

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results